.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,927,604

« Back to Dashboard

Claims for Patent: 8,927,604

Title:Diclofenac formulations and methods of use
Abstract: Methods and formulations are provided for treating migraine and other acute pain episodes using diclofenac, and formulations of diclofenac that provide both rapid and sustained relief from acute pain. Methods and formulations are also provided for treating symptoms that often accompany migraine and acute pain such as photophobia, phonophobia, nausea and vomiting.
Inventor(s): Reiner; Giorgio (Como, IT), Reiner; Alberto (Como, IT)
Assignee: APR Applied Pharma Research s.a. (Balerna, CH)
Application Number:13/742,871
Patent Claims: 1. A method of treating migraine associated with phonophobia or photophobia in a human patient in need thereof comprising: a) providing a liquid formulation comprising 25 mg. or 50 mg. of diclofenac or a pharmaceutically acceptable salt thereof, wherein said formulation: i) is provided as a powder formulation and dissolved or suspended in water immediately before administration, or as a liquid formulation that is ingested with or without further mixing; ii) optionally has been shown to achieve a C.sub.max of from about 1500 to about 2500 ng/ml; and iii) has been shown to achieve t.sub.max in from about 10 to about 25 minutes; and b) orally administering said formulation to a patient suffering from migraine associated with photophobia or phonophobia.

2. The method of claim 1 further comprising diagnosing said patient suffering from migraine as requiring sustained migraine relief for at least 24 hours.

3. The method of claim 1 wherein said liquid formulation comprises about 50 mg. of diclofenac potassium.

4. The method of claim 1 wherein said formulation has been shown to achieve t.sub.max in from about 10 to about 20 minutes.

5. The method of claim 4 wherein said formulation has been shown to achieve a C.sub.max of from about 1400 to about 2500 ng/ml.

6. The method of claim 4 wherein said formulation has been shown to achieve a C.sub.max of from about 1500 to about 2500 ng/ml.

7. The method of claim 1 wherein said formulation has been shown to achieve a C.sub.max of from about 1500 to about 2500 ng/ml.

8. The method of claim 1 wherein said formulation has been shown to achieve a C.sub.max of from about 1400 to about 2500 ng/ml.

9. The method of claim 4 wherein said formulation comprises approximately 25 mg. of diclofenac or a pharmaceutically acceptable salt thereof, and said formulation has been shown to achieve a C.sub.max of from about 850 to about 1150 ng/ml.

10. A method of treating recurrent migraine in a human patient in need thereof suffering from migraine comprising: a) providing a liquid formulation comprising about 25 mg. or 50 mg. of diclofenac or a pharmaceutically acceptable salt thereof, wherein said formulation: i) is provided as a powder formulation and dissolved or suspended in water immediately before administration, or as a liquid formulation that is ingested with or without further mixing; ii) optionally has been shown to achieve a C.sub.max of from about 1500 to about 2500 ng/ml; and iii) has been shown to achieve t.sub.tmax in from about 10 to about 25 minutes; and b) diagnosing a patient suffering from migraine as requiring sustained migraine relief for at least 24 hours; and c) orally administering said formulation to said patient.

11. The method of claim 10 wherein said patient suffers from headache pain and either photophobia or phonophobia or both.

12. The method of claim 10 wherein said liquid formulation comprises about 50 mg. of diclofenac potassium.

13. The method of claim 10 wherein said C.sub.max has an inter-subject variability of less than about 70%.

14. The method of claim 10 wherein said t.sub.max has an inter-subject variability of less than about 70%.

15. The method of claim 10 wherein said formulation has been shown to achieve t.sub.max in from about 10 to about 20 minutes.

16. The method of claim 10 wherein said formulation has been shown to achieve a C.sub.max of from about 1400 to about 2500 ng/ml.

17. The method of claim 10 wherein said formulation has been shown to achieve a C.sub.max of from about 1500 to about 2500 ng/ml.

18. The method of claim 15 wherein said formulation has been shown to achieve a C.sub.max of from about 1400 to about 2500 ng/ml.

19. The method of claim 15 wherein said formulation has been shown to achieve a C.sub.max of from about 1500 to about 2500 ng/ml.

20. The method of claim 15 wherein said formulation comprises approximately 25 mg. of diclofenac or a pharmaceutically acceptable salt thereof, and said formulation has been shown to achieve a C.sub.max of from about 850 to about 1150 ng/ml.

21. A method of treating migraine in a human patient in need thereof comprising: a) providing a liquid formulation comprising about 25 mg. or 50 mg. of diclofenac or a pharmaceutically acceptable salt thereof, wherein said formulation: i) is provided as a powder formulation and dissolved or suspended in water immediately before administration, or as a liquid formulation that is ingested with or without further mixing; ii) optionally has been shown to achieve a C.sub.max of from about 1500 to about 2500 ng/ml; and iii) has been shown to achieve t.sub.max in from about 10 to about 20 minutes; and b) orally administering said formulation to a patient suffering from migraine, wherein said migraine is defined as a disease manifested in a population of patients by periodic attacks of headache pain, nausea, photophobia and phonophobia.

22. The method of claim 21 wherein said patient suffers from headache pain and either photophobia or phonophobia or both.

23. The method of claim 21 further comprising diagnosing said patient suffering from migraine as requiring sustained migraine relief for at least 24 hours.

24. The method of claim 21 wherein said C.sub.max has an inter-subject variability of less than about 70%.

25. The method of claim 21 wherein said t.sub.max has an inter-subject variability of less than about 70%.

26. The method of claim 21 wherein said liquid formulation comprises about 50 mg. of diclofenac potassium.

27. The method of claim 21 wherein said formulation has been shown to achieve t.sub.max in from about 10 to about 20 minutes.

28. The method of claim 21 wherein said formulation has been shown to achieve a C.sub.max of from about 1400 to about 2500 ng/ml.

29. The method of claim 21 wherein said formulation has been shown to achieve a C.sub.max of from about 1500 to about 2500 ng/ml.

30. The method of claim 27 wherein said formulation has been shown to achieve a C.sub.max of from about 1400 to about 2500 ng/ml.

31. The method of claim 27 wherein said formulation has been shown to achieve a C.sub.max of from about 1500 to about 2500 ng/ml.

32. The method of claim 27 wherein said formulation comprises approximately 25 mg. of diclofenac or a pharmaceutically acceptable salt thereof, and said formulation has been shown to achieve a C.sub.max of from about 850 to about 1150 ng/ml.

33. A method of treating acute pain in a human patient in need thereof for at least eight hours, comprising: a) providing an oral formulation comprising about 25 mg. or 50 mg. of diclofenac or a pharmaceutically acceptable salt thereof, wherein said formulation: i) optionally has been shown to achieve a C.sub.max of from about 1400 to about 2500 ng/ml; and ii) has been shown to achieve t.sub.max in from about 10 to about 35 minutes; and b) orally administering said formulation to a patient suffering from acute pain, no more than 3 total times in a 24 hour period; thereby providing pain relief to said patient for at least eight hours.

34. The method of claim 33 wherein said formulation has been shown to achieve t.sub.max in from about 10 to about 30 minutes.

35. The method of claim 33 wherein said acute pain is post-operative dental pain.

36. The method of claim 33 wherein said formulation has been shown to achieve a C.sub.max of from about 1500 to about 2500 ng/ml.

37. The method of claim 33 wherein said formulation has been shown to achieve a C.sub.max of from about 1400 to about 2500 ng/ml.

38. The method of claim 34 wherein said formulation has been shown to achieve a C.sub.max of from about 1400 to about 2500 ng/ml.

39. The method of claim 34 wherein said formulation has been shown to achieve a C.sub.max of from about 1500 to about 2500 ng/ml.

40. The method of claim 34 wherein said formulation comprises approximately 25 mg. of diclofenac or a pharmaceutically acceptable salt thereof, and said formulation has been shown to achieve a C.sub.max of from about 850 to about 1150 ng/ml.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc